Single-Injection Drug For Knee Osteoarthritis Approved By FDA
The company's shares rose about 33 percent to $45.98 in extended trading after the approval for Monovisc, which is already
single injection drug knee osteoarthritis approve fda company share rise percent  extended trading approval monovisc